Roger Svensson’s patented AI doctor Diagnosio uses logic to diagnose like a physician—now ready for global rollout.
He Saw the Future Before Silicon Valley Did
In a modest lab outside Stockholm, years before ChatGPT made artificial intelligence a global obsession, Roger Svensson was quietly developing a diagnostic system that could reshape medicine.
But unlike the flood of startups now racing to capitalize on AI trends, Svensson’s focus wasn’t on creating a flashy tool. His goal was more ambitious: to engineer a reasoning engine that could think like a physician, act faster than one, and improve outcomes across the healthcare system.
The result was Diagnosio, an AI diagnostic platform built around a core idea rarely explored in conventional systems—the ability to determine the next best step in a clinical investigation, not just guess a diagnosis.
With a U.S. patent now secured and the AI health market surging, the world may finally be ready for what Svensson built years ahead of the curve.
A Founder at the Intersection of Science, Finance, and Innovation
Roger Svensson is not your typical tech founder. With a PhD in medical physics from Karolinska Institutet and an MBA in finance, he has spent his career launching ventures at the intersection of medicine, technology, and systems thinking.
Throughout multiple startups in human and veterinary healthcare, one question remained central to his work: Why can’t machines reason their way to a diagnosis, rather than simply retrieve one?
“I wasn’t trying to replicate what doctors know,” Svensson explains. “I was trying to model how they think, especially when they’re uncertain or pressed for time.”
That led to a research-backed diagnostic approach built not on symptom classification, but on optimization and inference—asking what action would yield the most valuable next piece of information.
It is this subtle but powerful shift in methodology that makes Diagnosio unique, and potentially transformative.
Diagnosio: Optimizing the Diagnostic Journey
Diagnosio’s core is built on the principle of diagnostic inversion. Rather than offering a ranked list of probable conditions based on presented symptoms, it evaluates all possible next steps—be it a test, a question, or a physical observation—and recommends the one that maximizes diagnostic certainty.
This approach was validated in 2018 through a master’s thesis at KTH Royal Institute of Technology, where a neural network trained on simulated patient data achieved up to 99 percent classification accuracy. Scaled in design to manage over 20,000 cases, 6,000 diagnoses, and more than 200,000 observables, Diagnosio can handle the complexity of real-world clinical practice.
In February 2024, the system was awarded U.S. Patent 11,908,579 B2. The intellectual property is now listed for sale or licensing through Vibrant IP, a U.S.-based brokerage firm specializing in AI and healthcare patents.
From Research to Market, at the Right Time
Diagnosio was conceived before AI became a household term, which posed challenges during early development. Investor interest was limited. The market was not yet prepared for a system that required deeper understanding of probabilistic logic and clinical workflows.
Today, that climate has changed.
With the global AI healthcare market expected to exceed $500 billion by 2032, Diagnosio represents a rare opportunity to leap ahead—offering validated, protected technology with broad cross-sector applications.
“Diagnosio isn’t a chatbot,” Svensson says. “It’s an intelligence layer that can power everything from triage to second opinions to complex decision support. And it integrates perfectly with today’s conversational models.”
A Technology That Complements, Not Competes
Svensson views Diagnosio not as a rival to ChatGPT, Grok, or Gemini, but as the logic engine that can guide them.
“Language models communicate well, but they’re not designed to reason through a diagnostic process,” he notes. “Diagnosio does that. It can determine what data is missing, what test to recommend, and what action will move the case forward most efficiently.”
This complements the growing ecosystem of LLM-based medical tools, which often lack internal reasoning architecture. The system’s ability to integrate with voice assistants, chatbots, or telemedicine portals further enhances its potential value.
In comparison to industry leaders like Microsoft’s MAI-DxO, Tempus AI, or Aidoc, Diagnosio distinguishes itself through dynamic decision-making. It doesn’t just predict, it optimizes—giving it a performance and usability edge in real-time clinical settings.
Built for Medicine, Ready for More
While Diagnosio was designed for human healthcare, its logic applies equally well to other fields. In veterinary medicine, where communication barriers make diagnostics particularly difficult, the platform offers immediate utility. It can also be adapted for use in finance, engineering, or cybersecurity—any domain where outcomes depend on interpreting symptoms and refining decisions over time.
This cross-industry adaptability broadens the value of the patent and opens doors to a wide range of licensing and partnership opportunities.
A Founder Who Stayed the Course
Svensson’s story is not just one of innovation. It is also a testament to patience, discipline, and strategic foresight.
He built Diagnosio before the industry had a name for what he was doing. He protected the invention with a U.S. patent before generative AI dominated headlines. “This can potentially revolutionize the healthcare industry,” he says. “It lowers cost, speeds up diagnosis, and helps patients and providers focus on what matters most—clarity and action.”
An Invitation to Build What’s Next
The Diagnosio patent is now available for acquisition, licensing, or joint development. BraineHealth is seeking partners who can accelerate its deployment in clinical environments, digital health platforms, or cross-industry applications.
For those seeking a first-mover advantage in AI healthcare, this is a unique opportunity to lead with a proven foundation, rather than start from scratch.
Explore more at BraineHealth.com, connect through Vibrant IP, or follow ongoing updates via Facebook, X, and YouTube.
Because in a market full of imitators, Diagnosio offers something rare—an original.
